ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.42% | 13.72% | 8.11% | 47.96% | 30.75% |
| Total Depreciation and Amortization | -9.57% | -5.54% | -6.71% | 18.57% | -22.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 140.18% | -8.04% | 282.81% | -95.89% | -89.43% |
| Change in Net Operating Assets | 81.28% | -324.69% | 127.90% | 363.51% | -283.93% |
| Cash from Operations | 9.05% | -87.18% | 82.91% | 91.23% | -79.85% |
| Capital Expenditure | -- | 99.50% | 68.97% | 100.00% | 29.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 2,948.30% | -- | -- | -- |
| Cash from Investing | -- | 810.95% | 68.97% | -100.00% | 626.48% |
| Total Debt Issued | -- | -- | -- | -97.87% | -- |
| Total Debt Repaid | 53.67% | 94.91% | -371.32% | 97.28% | -459.02% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 538.63% | 1,549.98% | 281.33% | -98.03% | -114.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.37% | 145.25% | 94.76% | -100.81% | -525.76% |